Your Global Leader in Stem Cell Market Research
January 30, 2017, SAN ANTONIO – GenCure, a subsidiary of San Antonio-based biotech BioBridge Global, has entered a development and manufacturing agreement with stem cell technology developer StemBioSys Inc. of San Antonio. [Read more…]
Boston, January 25, 2017 – Cytonome/ST, LLC announces it has signed the first application specific agreement to license its proprietary GigaSortTM Technology for commercial scale cell therapy production. A premier pharmaceutical company has signed on for rights to use the technology for their explicit disease indication. They will manufacture a critical cell therapy to address one of the major diseases afflicting aging populations globally.
The GigaSort Platform is an application specific laser-based cell sorter that allows the identification, characterization, and isolation of highly purified cell populations. [Read more…]
High-quality Human iPSC-based discovery services for CNS and pain research.
| January 26, 2017 – Cellectricon AB and Censo Biotechnologies Ltd are announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research. [Read more…]
Akron Biotech is part of the Advanced Regenerative Manufacturing Institute (ARMI) consortium to develop next-generation manufacturing processes and technologies for cells, tissues and organs. The ARMI will receive nearly $300 million in public-private investment from leading manufacturers, universities, nonprofit organizations and the federal government to develop scalable manufacturing processes for engineered tissues and organs.
Melbourne, Australia; 23 January 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has successfully completed a placement of approximately 9.23 million fully-paid ordinary shares at a price of $0.65, for gross proceeds of A$6.0 million before costs (“Placement”). The Placement was made to existing and new sophisticated and institutional investors. Settlement of the Placement, which was heavily over-subscribed, is expected to occur on or about 27 January 2017 with the shares to be issued on 30 January 2017. The Placement shares will be issued under Cynata’s existing placement capacity under Listing Rules 7.1 and 7.1A, and accordingly will not require shareholder approval. [Read more…]
